Manabu Kageyama

Publications (3)10.35 Total impact

• Article: Long-term benefits of monteplase before coronary angioplasty in acute myocardial infarction.

  Teruo Inoue, Ryoichi Nishiki, Manabu Kageyama, Ryuji Chida, Terumi Hayashi, Kan Takayanagi, Yutaka Hikichi, Koichi Node
  [show abstract] [hide abstract]
  ABSTRACT: Patients with acute myocardial infarction were randomly assigned to receive direct percutaneous coronary intervention (PCI) or pretreatment with intravenous monteplase followed by PCI. Although the combination of monteplase and PCI did not alter mortality compared with direct PCI, there was a dramatic reduction in the cardiac event rate over a 2-year follow-up compared with direct PCI.
  The American Journal of Cardiology 03/2005; 95(4):506-8. · 3.37 Impact Factor
• Article: Therapeutic potential of monteplase in acute myocardial infarction.

  Teruo Inoue, Ryoichi Nishiki, Manabu Kageyama, Koichi Node
  [show abstract] [hide abstract]
  ABSTRACT: Thrombolysis with conventional thrombolytic agents prior to percutaneous coronary intervention (PCI) has had no impact on the treatment of acute myocardial infarction (AMI). However, the development of mutant tissue type plasminogen activators (mt-PA) has prompted us to reassess the combination of thrombolysis and PCI. Monteplase is a newly developed mt-PA that can be administered as a single intravenous bolus injection. The results of the COMA (COmbining Monteplase with Angioplasty) trial, suggest that monteplase administration prior to emergent PCI in AMI improves 6-month outcomes and possibly the long-term prognosis of myocardial infarction. Combining monteplase administration on presentation at a community hospital with prompt transfer to a tertiary center for PCI would be an ideal strategy for the treatment of AMI.
  American Journal of Cardiovascular Drugs 02/2005; 5(4):225-31. · 1.77 Impact Factor
• Article: Therapeutic potential of monteplase in acute myocardial infarction as a powerful thrombolytic agent for pretreatment of coronary intervention.

  Teruo Inoue, Ryoiochi Nishiki, Manabu Kageyama, Koichi Node
  [show abstract] [hide abstract]
  ABSTRACT: Thrombolysis with conventional thrombolytic agents followed by percutaneous coronary intervention (PCI) had no impact on the treatment of acute myocardial infarction (AMI). However, the development of mutant type plasminogen activator (mt-PA) has prompted us to reassess the combination of thrombolysis and PCI. Monteplase (Eisai, Co. Ltd., Tokyo, Japan) is a newly developed mt-PA that can be administrated as a single intravenous bolus injection. We initiated a clinical trial [Combining Monteplase with Angioplasty (COMA)] to evaluate the effectiveness of monteplase followed by PCI. The AMI patients were randomly assigned to receive PCI following pretreatment with a single bolus intravenous injection of monteplase or direct PCI without monteplase. The initial coronary angiography prior to PCI showed that 36.2% of patients in the monteplase group achieved Thrombolysis in Myocardial Infarction (TIMI) 3 flow in the infarct-related artery, compared with in only 7.9% of patients in the direct PCI group (P < 0.0001). During 24 months following PCI, major cardiac events occurred in 27.7% of patients in the monteplase + PCI group, and in 46.7% of patients in the direct PCI group without monteplase (P < 0.05). Thus, the ideal strategy for the treatment of AMI is the administration of monteplase upon arrival at a community hospital with a prompt transfer to a tertiary center for PCI.
  Cardiovascular Drug Reviews 01/2004; 22(4):320-33. · 5.21 Impact Factor